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Abstract

Introduction: Biocompatibility is Biocompatibility

Any biomaterial implanted into a living body elicits
a distinct local reaction. This reaction depends on the
physical, physico-chemical and chemical properties of
the material. The obvious term to designate this inherent
property of a biomaterial to induce a local reaction is
reactogenicity. Reactogenicity of a biomaterial is one of
the main factors determining (together with other properties of the implanted device) the bio(non)compatibility of
the implant. Such amplification of terminology which
establishes differences between biocompatibility as a
generalized characteristic of biomaterials in all their
interrelations with the host's organism and the influences
on local processes around implants, makes the biocompatibility concept more precise from a logical and
semantic point of view. The principal phase of the local
reaction to an implant is inflammation. Reactogenicity
manifests itself mainly in determining peculiarities of
this phase, and these peculiarities can be modulated by
modifying properties of the material. The practical
heuristic advantages of the reactogenicity concept are
associated with its quantitative character and with
turning attention to the possibility of regulating the local
reaction without crossing limits of biocompatibility.

It is universally recognized that implantation into a
living organism of any artificial device is accompanied
by a reaction of tissue coming into an immediate contact
with the implant. A problem arises - what term is to be
used to define precisely the property of biomaterials to
elicit a certain local reaction?
During recent years, the most widely applied term
for this purpose is biocompatibility, which was
approved, not without serious difficulties (Sefton, 1986),
by the 1986 Consensus Conference in Chester, UK. The
use of this term is based on the definition of biocompatibility adopted by the Conference ("The ability of a
material to perform with an appropriate host response in
a specific application") (Williams, 1988).
But if we consider the semantic contents of term
"compatible" formulated, e.g., by the Oxford Advanced
Learner's Dictionary of Current English (1980) as
"suited to, in accord with, able to exist in accord with",
we must agree that the term "biocompatibility" gives a
very broad, global, characteristic of biomaterials in all
their interrelations with the host's organism, systemic
reactions included (Murabayashi and Nose, 1986).
Though a very important one, the local reaction is only
part of these interrelations.
Besides, this definition does not discriminate
between properties of a material and an implant. Such a
complexity makes it not quite suitable to describe the
inherent properties of a given biomaterial. Moreover,
this complexity imparts to the term "biocompatibility" a
relative character (Boss et al. , 1995). This is the cause
of difficulties in quantitative estimation of a material
biocompatibility and even its evaluation as good or poor
(Hellman et al., 1994).
In the simplest terms, from the semantic and logical
points of view, to be biocompatible for a material,
means to be compatible with vital functions of the host.
To be compatible means to be compatible, and a material could be either compatible or not.
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Reaction to Biomaterials and Reactogenicity.
Role of Inflammation

implantation, by the mature connective tissue capsule
wrapping the implant (Sevastjanova et al., 1987; Spector
et al., 1989; Slutskii et al., 1992). During this process
of newly formed connective tissue maturation, specific
components are expressed by participating cells, providing integrity and stability of the scar (or capsular tissue
around the implant), and restoration of functions
(Thomas et al., 1995; Ehrlich, 1995).
Some manifestations of inflammation might be
modulated considerably by the influence of various
factors in a distinct range. To these modulating factors
belong the properties of biomaterials used in implantation, as we have shown in our earlier publications
(Slutskii et al. , 1992, 1994, 1995) and as was noted by
others (e.g., Nakamura et al., 1990). Thus, the noncomplicated inflammation is the main field where the
biomaterial reactogenicity operates. If "normality"
frontiers of inflammation are crossed, the material which
inflicts such a reaction is no more biocompatible.
The modulations of inflammatory events within the
above-mentioned limits under the influence of reactogenicity changes may be very variable. They may be
manifested by variations in the composition of cell
population (Kao et al., 1994) and by some structural and
compositional (quantitative) peculiarities of the
granulation tissue extracellular matrix. Intensification
and acceleration or, on the contrary, inhibition and
weakening of typical inflammatory phenomena could be
observed. For example, it was shown (Slutskii et al. ,
1984) that cellulose modified by addition of tertiary
ammonium groups, placed into subcutaneous tissue in
form of a cotton pellet, induces development of granulomas 3- to 4-fold enriched in glycosaminoglycans as
compared with granulomatous tissues induced by
unmodified cotton wool. Analogous abundance in
glycosaminoglycans was noted histochemically in the
wound tissue when the same modified cellulose was used
in the form of surgical threads; when sutured by these
threads, incision skin wounds showed a great acceleration in restoration of their biomechanical parameters.
Such qualitative and quantitative changes frnd
explanation in increased phenotypical lability of cells
participating in the inflammatory process (Gailit and
Clark, 1994) and in the existence of differential regulation of expression of various genes in actively
proliferating connective tissue (Bodo et al., 1994).
Differences in the course of non-complicated
inflammation and in subsequent events depending on
reactogenic properties of biomaterials may be
quantitated, and more and more sophisticated methods
have been elaborated for such quantitative investigation
during the last years (Hunt et al., 1994; Peppas and
Langer, 1994; Hunt and Williams, 1995). For the study
of cell adhesion and protein adsorption on the material

In order to obtain the characterization of a biomaterial effect on adjoining cells and tissues, one should
investigate the processes developing in these living
objects after a contact with a material, or, in other
words, the cell and tissue reaction (Williams, 1987;
Spector et al., 1989; Okada and Ikada, 1993). A possible term to designate the property of a biomaterial to
inflict a certain reaction is reactogenicity. Thus, we
define reactogenicity as an inherent property of a
biomaterial, depending on its physical (Bordji et al. ,
1996), physico-chemical and chemical peculiarities, to
elicit a distinct reaction from the side of biological
objects.
The influence of a biomaterial on behaviour of cells
coming in contact with its surface is a particular
manifestation of reactogenicity. This influence can be
explored either in vitro or in vivo (Thomson et al.,
1992; Charissou et al., 1996). Thus, Kao et al. (1994)
found in in vivo experiments differences in macrophage
adhesion and foreign body giant cells formation between
such polymers as polydimethylsiloxane, low density
polyethylene, and polyetherurethane.
But the main approach to the study of reactogenicity
of biomaterials is investigation of the in vivo reaction.
This reaction is a particular case of the wound healing
process (Sevastjanova et al., 1987; Schreuders et al. ,
1988; von Recum et al., 1993). In full analogy to wound
healing, inflammation (Spector et al., 1989) is the m~or
early stage of this process as the consequence of the
surgical procedure of implantation and the pure mechanical effect of the implanted foreign body, after adhesion
to the material surface of proteins and cells, first of all,
leukocytes and macrophages (Bagambisa et al., 1994).
Certainly, inflammation may relatively often and easily
take a pathological course (Tang and Eaton, 1995), but
the uncomplicated inflammation is a laudable part of a
normal process, a normal physiological response to
destruction of a vascularized tissue either by a simple
wounding, or by biomaterial implantation (Peppas and
Langer, 1994).
Inflammation sets into motion a sequence of cellular
and molecular processes (Clark, 1993) which lead to the
next, reparative, phase consisting of proliferation of
connective tissue, namely of its specialized kind :
reparative tissue. This tissue appears, at first , as socalled granulation tissue which is gradually transformed
into fibrous tissue (we proposed earlier to designate the
reparative tissue in the intermediate phase of its
development as "granulo-fibrous"). The last phase is
represented by the dermal part of cutaneous wound scar
(Kirsner and Eaglstein, 1993), or, in the case of
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surface, cellular and macromolecular composition of
granulo-fibrous tissue forming the capsule surrounding
the implant,
semiquantitative and
quantitative
(morphometric) histo-, cyto- and immunohisto(cyto)chemical methods provide the necessary data. As to
development of a connective tissue capsule around the
implanted biomaterial, a complex quantitative biochemical analysis is of especial interest (Sevastjanova et al.,
1987; Slutskii et al., 1992).
Differences in reactogenicity ofbiomaterials and the
possibility to evaluate quantitatively this property allow
to regulate the process induced by implantation by using
of materials, possessing different or modified reactogenicity. This is of outmost practical significance since
the inflammatory phase determines the future development of the fibrotic tissue.

Biomaterial

Other properties
(toxicity, mutagenity,
teratogenity, chemical
signals)

Non-specific
reactogenicity
(influence on
inflammation and
its after-effects)

Specific
reactogenicity
(bioactivity)

Reactogenicity but not Reactivity
Countless papers devoted to biological reactions to
biomaterials and hence to reactogenic properties of the
latter could be found. It is important to point out the
incorrectness of the use in this connection of the term
"reactivity" . When we speak about "reactivity of a biomaterial", we mean the conduct of implanted material in
biological environment, its property to react to conditions in the host's organism, to undergo distinct
changes under these conditions (Gatti et al., 1994;
Hoffman, 1995; Pohunkova and Adam, 1995). In this
context, the material is the object of the influences of the
host. While, the ability of a biomaterial to play an active
role, to generate a definite biological reaction is to be
defined by the term reactogenicity.

Figure 1. Schematic v1ew of relationship between
terminology.
be included in the program of their experimental testing.

Concluding Remarks
The proposed concept of reactogenicity is by no
means antagonistic to the biocompatibility concept.
Biocompatibility is a generalization, which combines all,
sometimes contradictory, influences of a biomaterial on
the living organism. Owing to this complex matter, biocompatibility is difficult, if possible, to quantify. A
biomaterial is either biocompatible or not; a non-biocompatible material may be transformed into a biocompatible one (e.g., by purification), but in this case we
encounter not an "improvement" of biocompatibility
(Piskin, 1995), but a principal qualitative change of the
material.
The reactogenicity concept supplements the biocompatibility concept by picking out one part of
biocompatibility, namely local influences of a biomaterial on contacting tissues and cells. These influences
are quite quantifiable (e.g., by morphometric and quantitative biochemical methods), and this provides a basis
for modulation and regulation of the reactogenic properties of biomaterials.
It is necessary to stress that the semantic and logical
analysis of defmitions relating to problems of biocompatibility and reactogenicity of biomaterials is not a

Reactogenicity and Bioactivity
A widely used concept (and term) in biomaterial
science is bioactivity; therefore the question arises about
the difference between bioactivity and reactogenicity.
The answer to this question could be found in the apt
defmition of bioactivity approved by the Chester Consensus Conference: a material is defined as bioactive if
it has been designed to induce specific biologic activity.
E. g., some biomaterials for bone surgery possess such
specific activity. These materials are characterized by
the ability to form direct chemical bonds between
implant and surrounding bone tissue (osteointegration) or
to induce osteogenesis being implanted into the bone,
without pronounced inflammatory stage (Galante et al. ,
1991; S0balle, 1993; Ungersbock et al., 1994). Thus,
bioactivity may be considered as a specialized variety of
reactogenicity. The unspecific reactogenicity manifests
itself in full if these materials contact with soft tissues
and the exploration of their reactogenic properties should
139
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purely terminological one. It focuses the attention of
researchers on chemical, physico-chemical and physical
characteristics of biomaterials as they manifest themselves in local interactions with living objects. It also
turns attention to possible approaches of modifying and
thus regulating contact biological reactions to biomaterials and achieving in this way better results in
medical practice.
Our reasoning is schematically illustrated in Fig. I.
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material. Implants are not mentioned; indeed they should
not be since biomaterials and biocompatibility are not
confmed to implantable devices.
We all accept that biocompatibility involves and
incorporates many different mechanisms associated with
the interactions between materials and tissue. It does
seem to me to be illogical to pick out parts of these
processes and to designate them as reactogenicity. There
is no doubt that materials influence inflammation but
why do we need a new term to characterize them. It is
also far from clear why "reactogenicity" is "the most
simple and obvious term" in this respect since it is not
in any of my dictionaries and has no obvious etymological credentials.
I have often made the plea that new words are not
introduced into our vocabulary unnecessarily. This point
will be covered in considerable detail in a forthcoming
publication (Williams, 1996). The main issue is whether
a new term serves any useful function. I personally
cannot fmd any purpose for reactogenicity.
Authors: Successful efforts undertaken during the last
years in order to develop and improve methods of
quantifying the tissue response (reaction!) to implanted
materials (Peppas and Langer, 1994; Hunt and Williams,
1995) clearly illustrate the growing interest of
biomaterial scientists in the local (contact) reaction
elicited by biomaterials. In our opinion, the next logical
step in this tendency is to single out this special aspect
of interrelations of a biomaterial and the living body, an
aspect which is of great importance for the characterization of the given biomate1ial, from the generalized
biocompatibility concept. Therefore, we propose in this
context the term reactogenicity as a necessary addition
to the term biocompatibility.

B. Ratner: Slutskii and Vetra are to be commended for
their interest in addressing the difficult subject of
biocompatibility. Unfortunately, I do not believe their
concept of reactogenicity offers clarification on this
complex topic.
The definition of biocompatibility adopted at a
consensus conference on defmitions in biomaterials, is
"the ability of a material to perform with an appropriate
host response in a specific application. " Although this
defmition is perfect in that there are no exceptions to it,
it offers no insight into how to measure biocompatibility
or how to engineer better biocompatibility into materials.
To delve more deeply into this subject of biocompatibility, we must examine the factors that clearly
influence biocompatibility: toxicology, implant design,
surgeon skill, implant movement, biodegradation and
interfacial reactions between biological components and
materials. Toxicology, the examination of leachables, is
a well-established field. Methods are in place for accu-

Discussion with Reviewers
D.F. Williams: As originator of the Consensus
Conference on Definitions on Biomaterials, and as the
person whose name is most usually associated with the
definition of the term Biocompatibility which emerged
from this conference, I have consistently argued that this
definition would need to evolve over time. I have always
hoped, however, that the evolution would serve to
clarify our understanding and application of this term. I
regret that I do not see the present paper and the concept
of reactogenicity as a clarification of these issues.
The defmition of biocompatibility is of course a
generalization, and it is self-evident that it cannot be
quantified by a single parameter. The authors here are
wrong to contend that it cannot discriminate between a
material and an implant. Indeed it does just that because
it specifically states that it refers to the ability of a
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rate toxicological assessment of biomaterials. Riomaterials should not leach cytotoxic components, and we
know how to make them so they do not. Implant design
is the province of the mechanical and chemical engineer.
Both disciplines are well established and embody solid
design principles. There is little that the biomaterial
scientist can add there. Surgeon skill is important, and
it is well established that in the hands of a skilled
surgeon, a given implant will perform better than in the
hands of a less skilled surgeon. Thus, variables driving
this factor are in the hands of the surgeon, and the
biomaterials designer can only make minimal contributions to this area. Implant movement will adversely
affect apparent biocompatibility. Implant movement can
be controlled through both good mechanical design and
good surgeon skill. An implant should not biodegrade,
unless it is intended to. We know much about designing
for biostability, and measuring the toxicological
consequences of biodegradation. Finally, this brings us
the interfacial interactions between the biomaterial and
the biology. I believe the concept of "reactogenicity"
proposed by Slutskii and Vetra encompasses, in part,
this interfacial reaction. Unfortunately, we know
remarkably little about the nature of this reaction, and
consequences of various reactions for healing and
implant success.
The interfacial reaction can be measured and quantified in many in vitro systems, for example, protein
adsorption, complement activation, cell attachment, cell
growth, platelet interaction. The problem is, that except
in a few limited cases, there has been remarkably poor
correlation between what is measured in vitro, and the
relevant in vivo reaction. Although quantitative data are
obtained and papers are published, the relevance to the
understanding of the biocompatibility or performance of
medical implants has been almost insignificant. What
accounts for this?
The fundamental difference between an in vitro and
an in vivo system must be considered. The in vitro
system can contain many of the components present in
the in vivo system in order to model the in vivo system.
However, the one "component" that will always be
missing is the rest of the organism. The chemical signals
(cytokines, chemokines, selectins, etc) coming from the
cells interacting with the adsorbed protein layer on the
biomaterial signal other cell and organ system in the
body with instructions - how to respond to this injury
associated with the implanted medical device. In vitro,
the signals from the cells "fall on deaf ears. " Their
intended receptors, normally found elsewhere in the
body, are missing.
I believe the future of biomaterials resides with
materials that tum on precise signalling pathway in the
body, as opposed to the largely non-specific reaction

triggered by our ex1stmg materials. These future
materials might be referred to using another term that
Slutskii and Vetra discuss - bioactive. But they will be
more that "bioactive". They will inhibit non-specific
events while amplifying specific reactions.
Thus, to come back to words and definitions, the
words and phrases I find useful in describing the
biological reaction component of biocompatibility are
biointeraction, bioactive, receptor-ligand interaction, cell
signaling, healing and reconstruction. I, personally,
remain unconvinced for the need for "reactogenicity" .
Authors: We started the present discussion with the goal
of making the biomaterial properties which manifest
themselves in vivo in, as you call it, "interfacial
interactions between the biomaterial and the biology"
more precise and concrete. We do not think that the
term "biocompatibility" in its accepted meaning of today
is fully adequate in this context. On the other hand, the
list of words and phrases you propose for the future to
describe the biological reaction (!) component of
biocompatibility contains only one term concerning the
biomaterial properties - "bioactivity", and this is
evidently insufficient to cover the whole problem. In our
opmwn,
the semantically too broad term
"biocompatibility" and the too specialized one
"bioactivity" need to be supplemented by an intermediate
term, and a quite possible candidate here is reactogenicity. Moreover, we hope that the introduction of this
concept may to a certain extent promote the brilliant
future of biomaterials you delineated in your essay.
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